Relay Therapeutics, Inc. (RLAY) Stock Forecast
RLAY analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.77 / 5 from 13 analysts
- Price target
- $27.58 average of analyst targets
- Upside to target
- +69.4% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.40
- 52-week range
- $6.05 – $20.75
RLAY analyst ratings
13 analystsNumber of analysts at each rating.
RLAY price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
RLAY earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.40 | −$0.43 | −$0.36 | −$0.43 | +6.7% | 11 |
| Current fiscal year (2026) | −$1.61 | −$1.72 | −$1.47 | −$1.61 | −0.2% | 11 |
| Next fiscal year (2027) | −$1.63 | −$1.83 | −$1.11 | −$1.61 | −1.1% | 11 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
RLAY revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $1.6M | $0 | $13.5M | 0.0% | 10 |
| Current fiscal year (2026) | $11.2M | $3.0M | $42.0M | −27.3% | 12 |
| Next fiscal year (2027) | $17.9M | $0 | $71.6M | +60.5% | 12 |
RLAY EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
RLAY revenue: reported and forecast
RLAY EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.39 | −$0.42 | −$0.40 | −$0.40 | −$0.40 | +2.5% | 3 up · 6 down |
| Current fiscal year (2026) | −$1.53 | −$1.63 | −$1.62 | −$1.61 | −$1.61 | +5.3% | 1 up · 8 down |
| Next fiscal year (2027) | −$1.65 | −$1.64 | −$1.64 | −$1.64 | −$1.63 | −1.2% | 1 up · 5 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
RLAY earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; RLAY beat in 10 of 12.
What analysts expect from RLAY
13 analysts cover Relay Therapeutics; their consensus rating is strong buy (4.77 on a 1–5 scale, where 5 is a strong buy). The average price target is $27.58, 69.4% above the latest close of $16.28. Analysts expect earnings of −$1.61 per share for 2026, −0.2% from a year earlier. For 2027 the average estimate is −$1.63 per share on revenue of $17.9 million. Relay Therapeutics beat the EPS estimate in 10 of the last 12 quarters.
Related: RLAY income statement, RLAY key metrics, RLAY chart. See the RLAY stock overview for the latest quote and news.
RLAY forecast FAQ
What is Relay Therapeutics's price target?
The average analyst price target for Relay Therapeutics is $27.58, 69.4% above the latest close of $16.28.
Is Relay Therapeutics a buy, hold or sell?
Of 13 analysts covering Relay Therapeutics, 10 rate it a strong buy, 3 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Relay Therapeutics's EPS forecast?
Analysts forecast −$1.61 per share for 2026 (range −$1.72 to −$1.47); for 2027 the estimate is −$1.63.
What is Relay Therapeutics's revenue forecast?
The average revenue estimate for 2026 is $11.2 million, growth of −27.3%; for 2027 it is $17.9 million.
When does Relay Therapeutics report earnings?
Relay Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $-0.40.
Does Relay Therapeutics usually beat earnings estimates?
Relay Therapeutics reported EPS at or above the analyst estimate in 10 of the last 12 quarters.